As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk A/S (NYSE: NVO) is one of the Most Undervalued International Stocks According to Analysts. On August 19, TD ...

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Lexicon is pivoting towards biotech research. LXRX stock is highly speculative. Read here for key updates on Pilavapadin ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

"Carpet exports face tariffs of 52.9%, jeopardizing livelihoods in Bhadohi, Mirzapur, and Srinagar, while Turkey, Pakistan, ...

Health-care companies fell as traders continued to flee the sector. Shares of companies such as UnitedHealth Group, Novo Nordisk and Eli Lilly, which are already in the red for 2025, sank further.

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S.